作者: A. Betriu , M. Heras , G. Sanz
DOI: 10.1007/978-94-009-1333-2_70
关键词:
摘要: In the past few years we have learned that myocardial infarction is a relatively gradual process can be influenced by several interventions [1]. this regard, reduction of infarct size has been major clinical issue, since amount preserved myocardium will definitely influence outcome patients with [2–5]. Among all aimed at reducing size, recanalization occluded vessel thrombolytic agents generated an increasing interest. Early trials began 25 ago and dealt mainly intravenous streptokinase (SK) [6, 7]. It Rentrop, however, who deserves credit for his remarkable work use intracoronary SK [8, 9], route administration first applied Chazov [10] potentiated later angiographic documentation coronary artery thrombosis as cause acute occlusion [11]. We now gained great deal experience in treatment using either or [12]. Nevertheless, questions regarding therapy evolving remain unsettled. particular, thrombolysis on both long-term mortality, critical time interval intervention to initiated, best drug, its optimal dose administration, management residual stenosis unknown.